These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 11443562)
81. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. Meissner HC; Groothuis JR; Rodriguez WJ; Welliver RC; Hogg G; Gray PH; Loh R; Simoes EA; Sly P; Miller AK; Nichols AI; Jorkasky DK; Everitt DE; Thompson KA Antimicrob Agents Chemother; 1999 May; 43(5):1183-8. PubMed ID: 10223933 [TBL] [Abstract][Full Text] [Related]
82. A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults. Aliprantis AO; Wolford D; Caro L; Maas BM; Ma H; Montgomery DL; Sterling LM; Hunt A; Cox KS; Vora KA; Roadcap BA; Railkar RA; Lee AW; Stoch SA; Lai E Clin Pharmacol Drug Dev; 2021 May; 10(5):556-566. PubMed ID: 33125189 [TBL] [Abstract][Full Text] [Related]
83. Respiratory syncytial virus: old challenges and new approaches. Chávez-Bueno S; Mejías A; Jafri HS; Ramilo O Pediatr Ann; 2005 Jan; 34(1):62-8. PubMed ID: 15693217 [TBL] [Abstract][Full Text] [Related]
84. Clinical characteristics and treatment outcomes among respiratory syncytial virus (RSV)-infected hematologic malignancy and hematopoietic stem cell transplant recipients receiving palivizumab. Permpalung N; Mahoney MV; McCoy C; Atsawarungruangkit A; Gold HS; Levine JD; Wong MT; LaSalvia MT; Alonso CD Leuk Lymphoma; 2019 Jan; 60(1):85-91. PubMed ID: 29947555 [TBL] [Abstract][Full Text] [Related]
85. Effect of digestion on stability of palivizumab IgG1 in the infant gastrointestinal tract. Lueangsakulthai J; Kim BJ; Demers-Mathieu V; Sah BNP; Woo Y; Olyaei A; Aloia M; O'Connor A; Scottoline BP; Dallas DC Pediatr Res; 2021 Aug; 90(2):335-340. PubMed ID: 33214672 [TBL] [Abstract][Full Text] [Related]
86. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Wu H; Pfarr DS; Losonsky GA; Kiener PA Curr Top Microbiol Immunol; 2008; 317():103-23. PubMed ID: 17990791 [TBL] [Abstract][Full Text] [Related]
87. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Boeckh M; Englund J; Li Y; Miller C; Cross A; Fernandez H; Kuypers J; Kim H; Gnann J; Whitley R; Clin Infect Dis; 2007 Jan; 44(2):245-9. PubMed ID: 17173225 [TBL] [Abstract][Full Text] [Related]
88. Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. (American Academy of Pediatrics). Canfield SD; Simoes EA Pediatr Ann; 1999 Aug; 28(8):507-14. PubMed ID: 10483596 [No Abstract] [Full Text] [Related]
89. A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study. Piñana JL; Hernández-Boluda JC; Calabuig M; Ballester I; Marín M; Madrid S; Teruel A; Terol MJ; Navarro D; Solano C Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28544152 [TBL] [Abstract][Full Text] [Related]
90. In vivo selection of respiratory syncytial viruses resistant to palivizumab. Zhao X; Sullender WM J Virol; 2005 Apr; 79(7):3962-8. PubMed ID: 15767398 [TBL] [Abstract][Full Text] [Related]
91. Respiratory syncytial virus infection in children admitted to hospital but ventilated mechanically for other reasons. von Renesse A; Schildgen O; Klinkenberg D; Müller A; von Moers A; Simon A; J Med Virol; 2009 Jan; 81(1):160-6. PubMed ID: 19031467 [TBL] [Abstract][Full Text] [Related]
92. Case management for pediatric respiratory syncytial virus outcomes. Deming LM Case Manager; 2002; 13(4):72-4. PubMed ID: 12131912 [No Abstract] [Full Text] [Related]
94. RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors. van Mechelen L; Luytjes W; de Haan CA; Wicht O Antiviral Res; 2016 Aug; 132():1-5. PubMed ID: 27185625 [TBL] [Abstract][Full Text] [Related]
95. The quest for an efficacious antiviral for respiratory syncytial virus. Torrence PF; Powell LD Antivir Chem Chemother; 2002 Nov; 13(6):325-44. PubMed ID: 12718405 [TBL] [Abstract][Full Text] [Related]